View Older Stories View More Recent Stories
-
Humacyte (HUMA) PT Lowered to $2 at BTIG
-
Humacyte, Inc. (HUMA) Tops Q1 EPS by 3c
-
Humacyte names Dr. Todd Rasmussen as chief surgical officer
-
H.C. Wainwright Reiterates Buy Rating on Humacyte (HUMA)
-
Humacyte realigns ex-US rights to Symvess with Fresenius Medical Care
-
Humacyte receives Israeli regulatory acceptance for vascular trauma product
-
Humacyte (HUMA) PT Lowered to $1 at Piper Sandler as 'Symvess Sales Fall Short'
-
Humacyte (HUMA) PT Lowered to $1 at TD Cowen
-
Humacyte (HUMA) PT Lowered to $3 at BTIG
-
Humacyte, Inc. (HUMA) Reports In-Line Q4 EPS
-
BTIG on Humacyte (HUMA): stock appreciation limited NT, though updates expand Symvess utility
-
Humacyte secures $1.475 million Saudi Arabia purchase commitment
-
Humacyte suspends $60 million stock offering program
-
D. Boral Capital stays Buy on Humacyte (HUMA) following MAA submission in Israel
-
Humacyte submits application for Symvess approval in Israel
-
BTIG Reiterates Buy Rating on Humacyte (HUMA)
-
Humacyte receives DoD funding for bioengineered blood vessel procurement
-
Humacyte (HUMA) PT Lowered to $10 at Benchmark
-
Humacyte plans to file for marketing approval of Symvess in Israel
-
H.C. Wainwright Reiterates Buy Rating on Humacyte (HUMA)
-
Humacyte terminates stock sale agreement with Jefferies
-
Humacyte (HUMA) PT Lowered to $11 at Benchmark
-
Humacyte, Inc. (HUMA) Tops Q3 EPS by 5c
-
Humacyte reports long-term results for combat injury treatment in Ukraine
-
Humacyte receives U.S. patent for bioengineered esophagus technology
-
Humacyte publishes CTEV coronary bypass data, plans human trials
-
Humacyte publishes study results on Symvess for vascular complications
-
Humacyte (HUMA) files $350M mixed shelf
-
Barclays Starts Humacyte (HUMA) at Overweight
-
Humacyte (HUMA) PT Lowered to $3.50 at TD Cowen
-
Benchmark Reiterates Buy Rating on Humacyte (HUMA)
-
Humacyte (HUMA) PT Lowered to $3 at H.C. Wainwright
-
Humacyte (HUMA) PT Lowered to $7 at BTIG
-
Humacyte, Inc. (HUMA) Misses Q2 EPS by 8c
-
Humacyte (HUMA) gains Defense Logistics Agency approval for Symvess access
-
Humacyte (HUMA) PT Lowered to $14 at Benchmark
-
Humacyte, Inc. (HUMA) Tops Q1 EPS by 48c
-
TD Cowen on Medical Supplies & Devices: 'Companies Least Affected by New Reciprocal Tariffs'
-
Benchmark Reiterates Buy Rating on Humacyte (HUMA)
-
Humacyte, Inc. (HUMA) Tops Q4 EPS by 9c
-
Humacyte (HUMA) CEO addresses concerns in NYT over FDA approval of Symvess
-
Humacyte (HUMA) PT Lowered to $5 at TD Cowen
-
Humacyte (HUMA) Announces Pricing of Public Offering of Common Stock
-
Humacyte (HUMA) Announces Proposed Public Offering of Common Stock
-
Humacyte (HUMA) PT Lowered to $7.50 at TD Cowen
-
Humacyte (HUMA) Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics
-
Benchmark Reiterates Buy Rating on Humacyte (HUMA)
-
Humacyte (HUMA) Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues
-
Humacyte (HUMA) Announces Commercial Launch of Symvess for Extremity Vascular Trauma
-
Humacyte (HUMA) and Pluristyx Announce Gene Editing Partnership
